Alnylam delivered a one-two punch in March, growing its portfolio of FDA-approved RNAi therapies with the addition of Amvuttra (vutrisiran) for transthyretin amyloid cardiomyopathy (ATTR-CM) and Qfitlia (fitusiran) for hemophilia. Qfitlia (fitusiran) is the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, and […]

Biogen has announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen’s presence in Kendall Square, integrating Biogen’s R&D and technical operations teams alongside its global and North American commercial organizations into a co-located […]

bluebird bio has entered into a definitive agreement to be acquired by private-equity firms Carlyle Group and SK Capital Partners in collaboration with a team of highly experienced biotech executives in a deal worth up to $96 million. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. Carlyle and SK Capital will […]

Stoke Therapeutics has entered into a collaboration with Biogen on the development and commercialization of zorevunersen, a potential first-in-class treatment for a form of epilepsy known as Dravet syndrome. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Upon closing of the transaction, Stoke will […]